H.R. 842: Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Signed Into LawPublic Law 119-75

Enacted as part of HR7148: Consolidated Appropriations Act, 2026· Feb 3, 2026

Sponsor

Jodey Arrington

Jodey Arrington

Republican · TX-19

Bill Progress

IntroducedJan 31
Committee 
Pass House 
Pass Senate 
Signed 
Law 

Latest Action · Oct 3, 2025

1/4

Reported (Amended) by the Committee on Ways and Means. H. Rept. 119-333, Part I.

One blood test, many cancers — and Medicare would pay

4 min readLast updated July 4, 2026

Why it matters

A single blood draw could screen for several cancers at once, long before symptoms show. H.R. 842 would open a path for Medicare to cover those tests, and it carries 338 cosponsors from both parties — one of the most widely backed health bills in the House. The catch is in the fine print: coverage would not begin until 2028, Medicare would pay for only one test every 11 months, and it would phase in by age, starting with the youngest beneficiaries and leaving out anyone already 68 or older when it launches.

H.R. 842 would add a new Medicare screening benefit for multi-cancer early detection tests beginning January 1, 2028. These tests are designed to look for several cancer types across different organs in a single test, with blood-based genomic tests as the main model.

Not every test would qualify. A test would have to be cleared or approved by the FDA, and federal health officials would still have to decide, through Medicare's national coverage process, that it is reasonable and necessary for Medicare patients.

Two big limits are built in. Medicare generally could not pay for more than one of these tests within 11 months, and it could not pay for anyone who had already reached age 68 by the start of 2028. That age cap rises by one year each year after that.

So the cutoff would be 68 in 2028, 69 in 2029, 70 in 2030, and onward. In practice, the benefit would start with beneficiaries in their mid-to-late 60s and open to older ages one year at a time. If a covered test later earns a top A or B rating from the U.S. Preventive Services Task Force, the age and frequency limits would drop away.

The bill also says this new coverage cannot be used to cut back existing Medicare screening for breast, cervical, colorectal, lung, or prostate cancer. It adds a screening option rather than swapping out the ones already in place.

H.R. 842 Bill Summary

What H.R. 842 actually does.

1

Medicare starts covering multi-cancer screening in 2028

Beginning January 1, 2028, Medicare could cover qualifying multi-cancer early detection screening tests for people with Part A or Part B coverage.

2

Only FDA-reviewed tests get in

A covered test must detect multiple cancers across multiple organs and must already be cleared, classified, or approved through the FDA pathway the bill lays out.

3

Blood-based tests are the main target

The bill is built around genomic blood tests that analyze cell-free DNA, though other biological-sample tests could qualify if federal officials find the results comparable.

4

One test every 11 months

Medicare generally could not pay for another multi-cancer screening test if you already had one in the previous 11 months.

5

Coverage phases in by age

Medicare could not pay in 2028 for anyone already 68 or older on January 1 of that year. The cutoff rises one year annually, so the benefit reaches older ages over time.

6

Existing cancer screenings stay in place

The bill says this new coverage cannot be used to reduce Medicare coverage for breast, cervical, colorectal, lung, or prostate cancer screening.

7

Payment is tied to a known benchmark

Before 2031, Medicare would pay the same rate it uses for a multi-target stool DNA screening test. Starting in 2031, it would pay the lower of that benchmark or the rate set under Medicare's lab payment system.

Who benefits from H.R. 842?

Medicare patients under the yearly age cap

If you are on Medicare and below the bill's age cutoff, H.R. 842 could give you access to a single test that screens for multiple cancers at once, starting in 2028.

People who want a blood-based screening option

The bill is aimed at blood tests, so patients who prefer a simple blood draw over more invasive procedures could gain a new Medicare-covered option if a product qualifies.

Companies developing multi-cancer detection tests

Test makers could gain a defined Medicare coverage pathway if their products clear the FDA process and win a national coverage decision from federal health officials.

Patients already using standard screenings

People who rely on mammograms, colonoscopies, lung scans, or prostate screening keep those benefits. The bill says this new coverage cannot replace them.

Who is affected by H.R. 842?

Beneficiaries 68 and older in 2028

If you had already turned 68 by January 1, 2028, Medicare payment for these tests would be excluded that year under the bill's age rule, until the rising cutoff reaches your age.

People who want repeat testing within a year

If you want another multi-cancer screening test within 11 months, Medicare generally would not pay for it unless the covered test later earns a top U.S. Preventive Services Task Force rating.

Federal health officials

Officials at Health and Human Services would have to decide which tests are reasonable and necessary for Medicare patients through the national coverage determination process.

Test developers without FDA clearance or approval

Products that have not gone through the required FDA review path would not qualify for this Medicare coverage route.

Share this story
Tracking floor activity — no debate on H.R. 842 yet. Updates when a legislator speaks on the record.

HR842 Legislative Journey

3 actions

House: Committee Action

Oct 3, 2025

119-333

Reported (Amended) by the Committee on Ways and Means. H. Rept. 119-333, Part I.

House: Vote: 43-0

Sep 17, 2025

43-0

Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 43 - 0.

House: Committee Action

Jan 31, 2025

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

About the Sponsor

Jodey Arrington

Jodey Arrington

Republican, Texas's 19th congressional district · 9 years in Congress

Committees: the Budget, Joint Economic Committee, Ways and Means

View full profile →

Cosponsors at time of passage (338)

This bill has 338 cosponsors: 185 Democrats, 153 Republicans, reflecting bipartisan support. Cosponsors represent 47 states: Alabama, Arkansas, Arizona, and 44 more.

185Democrats153Republicans·47 statesBipartisan

Cosponsor Coverage Map

Committee Sponsors

Ways and Means Committee

19D26R
|40 signed5 others

40 of 45 committee members cosponsored at the time

Energy and Commerce Committee

24D30R
|44 signed10 others

44 of 54 committee members cosponsored at the time

What laws does H.R. 842 change?

1 changes

Full Text

Sections Amended

Section 1834 of Social Security Act (42 U.S.C. 1395m)

adding at the end the following new subsection: ``(aa) Payment and Standards for Multi-Cancer Early Detection Screening Tests

H.R. 842 Quick Facts

Cosponsors
338
Terri Sewell
Richard Hudson
Raul Ruiz
Mariannette Miller-Meeks
Robin Kelly
+333 more
Committee
Ways and Means
Chamber
House
Policy
Health
Introduced
Jan 31, 2025

Reported (Amended) by the Committee on Ways and Means. H. Rept. 119-333, Part I.

Oct 3, 2025

Official Sources

H.R. 842 on Congress.gov

Official bill page with status, text, cosponsors, and actions for H.R. 842.

CMS National Coverage Determination Process

The bill requires federal health officials to use Medicare's national coverage determination process to decide whether a new multi-cancer test is reasonable and necessary.

FDA In Vitro Diagnostics

Multi-cancer early detection tests described in the bill would be regulated as in vitro diagnostic medical devices reviewed by FDA.

FDA Premarket Notification 510(k)

The bill references clearance under section 510(k) as one FDA pathway a qualifying test can use.

FDA De Novo Classification Request

The bill references classification under section 513(f)(2), which is FDA's De Novo classification pathway for certain new device types.

FDA Premarket Approval (PMA)

The bill also allows tests approved under section 515 of the Federal Food, Drug, and Cosmetic Act to qualify.

USPSTF Grade Definitions

The bill's age and frequency limits fall away if a covered test earns a grade of A or B from the U.S. Preventive Services Task Force.

About Legisletter

Legisletter is the advocacy platform that tracks every bill from introduction to Public Law — and connects the constituents affected by a bill to the legislators who vote on it.

Who is lobbying on H.R. 842?

9 organizations lobbying on this bill

Total filings: 44
EXACT SCIENCES CORPORATION
10
GRAIL, INC. (FORMERLY GRAIL, LLC)
10
JOHN HANCOCK LIFE INSURANCE COMPANY (USA) (FKA JOHN HANCOCK FIN. SERVICES, INC.)
4
NATIONAL MINORITY QUALITY FORUM ACTION NETWORK
4
GRAIL, INC
4
JOHN HANCOCK LIFE INSURANCE COMPANY (U.S.A.)
4
TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF GRAIL, LLC
3
CURING STOMACH CANCER: DEBBIE'S DREAM FOUNDATION
3
GRAIL, LLC
2

Showing 1-9 of 9 organizations

H.R. 842 Common Questions

What would H.R. 842 do?

It would let Medicare cover certain multi-cancer early detection tests starting in 2028. These tests are designed to screen for several cancers at once, usually from a single blood sample.

When would Medicare start covering these cancer blood tests?

Coverage would begin January 1, 2028, but only if a test meets the bill's standards and Medicare clears it through the national coverage process. Nothing is covered automatically.

Who could get a Medicare-covered multi-cancer test under H.R. 842?

People on Medicare Part A or Part B, as long as you are under the yearly age cutoff and have not had one of these tests in the past 11 months.

What is the age cutoff in H.R. 842?

It starts at 68 in 2028, then rises to 69 in 2029, 70 in 2030, and so on. It is based on your age as of January 1 that year, so the benefit begins with younger beneficiaries and reaches older ages over time.

How often would Medicare pay for one of these tests?

Generally no more than once every 11 months. That limit would drop away if a covered test later earns a grade of A or B from the U.S. Preventive Services Task Force.

Would H.R. 842 replace mammograms or colon cancer screening?

No. The bill says this new coverage cannot be used to cut existing Medicare screening for breast, cervical, colorectal, lung, or prostate cancer. It adds an option instead of swapping one out.

What would a covered test cost Medicare?

Before 2031, Medicare would pay the same rate it uses for a multi-target stool DNA screening test. Starting in 2031, it would pay the lower of that benchmark or the rate set under Medicare's lab payment system.

What is the current status of H.R. 842?

It was reported as amended by the House Ways and Means Committee and carries 338 cosponsors from both parties, making it one of the most widely backed health bills in the House.

Based on H.R. 842 bill text

H.R. 842 Bill Text

PDF

To amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.

Source: U.S. Government Publishing Office

Health Bills

9 related bills we're tracking

View all
H.R. 1262

Mikaela Naylon Give Kids a Chance Act

Michael McCaul
Michael McCaulR-TX
Cosponsor
Cosponsor
Cosponsor
Cosponsor
+309
313 cosponsors

Received in the Senate.

Dec 2, 2025

HouseHealth
H.R. 3514Gaining+7

Improving Seniors’ Timely Access to Care Act of 2025

Mike Kelly
Mike KellyR-PA
Cosponsor
Cosponsor
Cosponsor
Cosponsor
+293
297 cosponsors
+7 this month

Forwarded by Subcommittee to Full Committee by Voice Vote.

Jun 25, 2026

HouseHealth
H.R. 4206

CONNECT for Health Act of 2025

Mike Thompson
Mike ThompsonD-CA
Cosponsor
Cosponsor
Cosponsor
Cosponsor
+236
240 cosponsors
+3 this month

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Jun 26, 2025

HouseHealth
H.R. 7973

Momnibus Act

Lauren Underwood
Lauren UnderwoodD-IL
Cosponsor
Cosponsor
Cosponsor
Cosponsor
+208
212 cosponsors
+1 this month

Referred to the Subcommittee on Health.

Apr 20, 2026

HouseHealth
H.R. 999

Right to Contraception Act

Lizzie Fletcher
Lizzie FletcherD-TX
Cosponsor
Cosponsor
Cosponsor
Cosponsor
+206
210 cosponsors
+3 this month

Referred to the House Committee on Energy and Commerce.

Feb 5, 2025

HouseHealth
H.R. 12

Women’s Health Protection Act of 2025

Judy Chu
Judy ChuD-CA
Cosponsor
Cosponsor
Cosponsor
Cosponsor
+204
208 cosponsors
+1 this month

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Jun 24, 2025

HouseHealth
H.R. 879

Medicare Patient Access and Practice Stabilization Act of 2025

Gregory Murphy
Gregory MurphyR-NC
Cosponsor
Cosponsor
Cosponsor
Cosponsor
+191
195 cosponsors

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Jan 31, 2025

HouseHealth
H.R. 4611

EACH Act of 2025

Ayanna Pressley
Ayanna PressleyD-MA
Cosponsor
Cosponsor
Cosponsor
Cosponsor
+181
185 cosponsors

Referred to the Subcommittee on Health.

Dec 19, 2025

HouseHealth
H.R. 6130Surging+27

ASAP Act

Vern Buchanan
Vern BuchananR-FL
Cosponsor
Cosponsor
Cosponsor
Cosponsor
+169
173 cosponsors
+27 this month

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Nov 19, 2025

HouseHealth

Trending Right Now

Bills gaining momentum across Congress

Tracking Health in Congress? Monitor bills, track cosponsor momentum, and launch advocacy campaigns — all from one advocacy platform.